Unexpected sirolimus-stimulated airway hyperreactivity in lymphangioleiomyomatosis.


Journal

ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641

Informations de publication

Date de publication:
Jul 2023
Historique:
received: 11 05 2023
accepted: 20 05 2023
medline: 17 8 2023
pubmed: 17 8 2023
entrez: 17 8 2023
Statut: epublish

Résumé

Lymphangioleiomyomatosis (LAM) is a multisystem disease affecting primarily women, characterised in the lung by proliferation of LAM cells, abnormal smooth muscle-like cells with dysfunctional tuberous sclerosis complex genes. This dysfunction results in activation of mechanistic target of rapamycin (mTOR), leading to LAM cell proliferation. Sirolimus (rapamycin) is the only United States Food and Drug Administration-approved treatment for pulmonary LAM, resulting in decreased LAM cell growth/size and stabilised lung function [1].

Identifiants

pubmed: 37589458
doi: 10.1183/23120541.00305-2023
pii: 00305-2023
pmc: PMC10423980
pii:
doi:

Types de publication

Journal Article

Langues

eng

Informations de copyright

Copyright ©The authors 2023.

Déclaration de conflit d'intérêts

Conflict of interest: All authors declare no conflicts of interest and no competing interests.

Références

Chest. 2002 Feb;121(2):621-4
pubmed: 11834679
Eur Respir J. 2020 Jul 2;56(1):
pubmed: 32108050
Lancet Respir Med. 2021 Nov;9(11):1313-1327
pubmed: 34461049
Ann Am Thorac Soc. 2016 Mar;13(3):342-9
pubmed: 26799509
Am J Respir Cell Mol Biol. 2014 Feb;50(2):398-408
pubmed: 24053175
Am J Respir Crit Care Med. 2021 Aug 15;204(4):431-444
pubmed: 33882264
J Appl Physiol (1985). 2013 Apr;114(7):834-43
pubmed: 23305987
Ann Am Thorac Soc. 2019 Dec;16(12):1504-1517
pubmed: 31404502
Hum Pathol. 2016 Apr;50:34-42
pubmed: 26997436
Eur Respir J. 2010 Jan;35(1):14-26
pubmed: 20044458
J Am Heart Assoc. 2019 May 7;8(9):e010090
pubmed: 31030596
Front Pharmacol. 2022 Mar 04;13:850586
pubmed: 35308247
Chest. 2009 Dec;136(6):1596-1603
pubmed: 19447921
Am J Respir Crit Care Med. 2016 Sep 15;194(6):748-61
pubmed: 27628078

Auteurs

Wendy K Steagall (WK)

Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Mario Stylianou (M)

Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Gustavo Pacheco-Rodriguez (G)

Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Zu Xi Yu (ZX)

Pathology Facility, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Joel Moss (J)

Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Classifications MeSH